Clinical Development and Medical Affairs

Novartis is driven by innovation and progress, but foremost, we want to improve patient care.

Explore our medical research, clinical development, and what’s coming down the pipeline..

Clinical Trials

 

Working closely with the care community, Novartis is currently conducting a number of clinical trials to find new treatment options for cancer patients.

All compounds are either investigational or being studied for new indications. Efficacy and safety have not been established. There is no guarantee that they will become commercially available.

Web Search

Clinicaltrials.gov

ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions. The website is maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH).

Clinical Development Trials

Ascend Trials  

Trials for prospective participants who have a specific kind of non-small cell lung cancer (NSCLC) that is called anaplastic lymphoma kinase-positive (ALK+)

Geometry Trials 

A series of Phase I/II clinical trials for NSCLC patients with specific genetic abnormalities called MET dysregulations

Hunter Trials

A group of Novartis-sponsored clinical trials investigating the use of chimeric antigen receptor (CAR) T-cell therapies in relapsed or refractory (r/r) pediatric acute lymphoblastic leukemia (ALL) and adult diffuse large B-cell lymphoma (DLBCL)

Monaleesa Trials

Trials for prospective participants who have hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer

Signature Trials

A series of Phase II clinical trials for patients who have not responded, or have stopped responding to standard treatment, and who have been identified as having specific genetic alterations that may be driving the growth of their cancers

Solar Trials

A Phase III trial for prospective male and postmenopausal female participants with HR +, HER2-, advanced breast cancer that progressed on or after aromatase inhibitor treatment

 

 

Clinical Trial Seek Mobile App
Clinical Trial Seek Mobile App

Download on the App Store® 

Download on Google Play™

Independent Medical Education

Oncology Grants and Education

Novartis Oncology discovers and develops innovative products to treat patients with cancer, hematologic, and rare diseases. Novartis is committed to the advancement of these goals through professional education.

The Novartis Oncology Office of Grants and Education (OGE) supports independent accredited and nonaccredited medical education programs intended to provide nonpromotional, current scientific information to US health care professionals (HCPs) and to improve patient care. Supported programs must be compliant with all applicable legal and regulatory guidelines, consistent with federal laws and regulations and the ethical standards under which Novartis Pharmaceuticals Corporation (NPC) conducts business. Funding may never be linked to prescribing, purchasing, formulary status, or reimbursement activities.

 For more information on the grants process or to submit an educational grant request, please visit the Novartis Grants Central Station website at http://ngcs.novartis.com/.

OGE only manages grant requests for activities taking place in the United States.

Pipeline

View the depth and breadth of our research portfolio, with innovative compounds in all phases of development.

Search the Novartis Pipeline

Novartis Medical Information

We are committed to providing the most up-to-date, accurate, and timely medical information to HCPs.

Submit a Medical Inquiry

Real-time Medical Inquiry (with optional video)

Novartis Medical Infomation Mobile App
Novartis Medical Infomation Mobile App

Download on the App Store®

Download on Google Play™



App Store is a registered trademark of Apple Inc.
Google Play is a trademark of Google Inc.